Extrovis
As of the edition of 20 October 2026, Extrovis runs 3 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluorouracil | none listed | 2 |
| Triamcinolone acetonide | none listed | 3 |
| Sugammadex | Ends 2028 (exclusivity) | 0 |
A route B row is one company at one target.